Table 2.
Comparison of Baseline NIHSS Scores Between PA and Non‐PA Users According to Stroke Mechanisms After Applying Stabilized IPTW
| PA Users | Non‐PA Users | LSM Difference | p a | P b | |
|---|---|---|---|---|---|
| Total | 6.74 (6.39–7.10) | 7.26 (6.97–7.56) | −0.52 (−0.83 to −0.21) | 0.001 | |
|
LAA SVO |
6.91 (6.35–7.47) 5.32 (4.84–5.81) |
7.88 (7.47–8.29) 5.39 (5.00–5.78) |
−0.97 (−1.43 to −0.50) −0.07 (−0.41–0.27) |
<0.001 0.680 |
0.009 |
| CE | 8.19 (7.47–8.92) | 8.45 (8.05–8.85) | −0.25 (−1.01–0.51) | 0.513 |
Values presented are mean (95% confidence interval [CI]) or least‐square mean (95% CI), as appropriate.
p values are calculated by analysis of covariance with the generalized estimating equation method adjusting for age, atrial fibrillation, hypertension, diabetes mellitus, stroke, glucose, glycated hemoglobin, low‐density lipoprotein cholesterol, and interval from onset to presentation.
An interaction effect p value between prestroke aspirin use and TOAST classification.
NIHSS = NIH stroke scale; PA = prestroke aspirin; IPTW = inverse probability of treatment weighting; LSM = least‐square mean; LAA = large artery atherosclerosis; SVO = small vessel occlusion; CE = cardiac embolism; TOAST = Trial of ORG 10172 in Acute Stroke Treatment.15